Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CNR1 | P21554 | 15/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892068 | 0.94 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9893098 | 0.94 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892070 | 0.94 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL16254901 | 0.94 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892887 | 0.86 | CNR2 (0.76) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892027 | 0.86 | CNR2 (0.75) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892033 | 0.86 | CNR2 (0.75) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL9892826 | 0.84 | CNR2 (0.73) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL2126970 | 0.83 | CNR2 (0.90) | CNR2CNR1CYP2C8CYP2C19CYP2D6 | |
| SCHEMBL20458233 | 0.83 | CNR2 (0.90) | CNR2CNR1CYP2C8CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885CYP2C8 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.